Back to search

Article

<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer

2017-10-23

Abstract excerpt

<h4>Background</h4> BRAF mutation occurs in 8-15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF ( BRAFWT ) disease, stage II/III CC patients with BRAF mutant ( BRAFMT ) tumors have shorter overall survival after relapse; however, time-to-relapse is not significantly different. The aim of this investigation was to identify, and validate, novel pr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8683fc60-2329-5e29-beea-af9055f74382
DOI
10.1101/207639
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancerDOI 10.1101/207639
Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.Semantic proximity
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity
BCL-2 system analysis identifies high-risk colorectal cancer patientsSemantic proximity
Bcl-xL is an oncogenic driver in colorectal cancer.Semantic proximity
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.Semantic proximity
Gradient Boosting Machine based prediction of chemotherapy response and role of p53 mutational and smoking status for progression free survival in metastatic colorectal cancerSemantic proximity
A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity
MCL1 nuclear translocation induces chemoresistance in colorectal carcinomaSemantic proximity
CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.Semantic proximity
Select a neighboring publication to make it the new centre.